Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocort placebo-controlled phase IIa study in active ulcerative colitis
NL-OMON40072Phase 2Active, not recruiting
- Sponsor
- Enceladus Pharmaceuticals
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of hydrocortisone in autoimmune colitis (2 arms), sponsored by Enceladus Pharmaceuticals. Primary endpoints: Frequency of serious adverse events, Frequency of adverse events and 1 more. Started Oct 2012; status: active, not recruiting.
02
Drugs
hydrocortisone
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON40072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40072.